From AbbVie’s upadacitinib to new gene therapies: Pharma’s 2019 blockbuster launches, ranked


The biopharma industry will see seven blockbuster launches this year, according to Clarivate’s annual “Drugs to Watch” list for 2019! See how they rank:

  1. AbbVie’s upadacitinib
  2. Novartis’ Zolgensma
  3. AstraZeneca & FibroGen’s roxadustat
  4. Alexion’s Ultomiris
  5. Boehringer Ingelheim & AbbVie’s Skyrizi
  6. Aimmune’s AR-101
  7. bluebird bio’s LentiGlobin

Read the full article at…


Comments are closed.

Read previous post:
HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey

According to an annual patient group opinion report from PatientView, 41% thought the pharma industry's reputation was “excellent” or “good”...